Genovate Biotechnology Co Ltd - Asset Resilience Ratio
Genovate Biotechnology Co Ltd (4130) has an Asset Resilience Ratio of 20.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Genovate Biotechnology Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Genovate Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Genovate Biotechnology Co Ltd's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Genovate Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Genovate Biotechnology Co Ltd (4130) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$312.92 Million | 20.77% |
| Total Liquid Assets | NT$312.92 Million | 20.77% |
Asset Resilience Insights
- Good Liquidity Position: Genovate Biotechnology Co Ltd maintains a healthy 20.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Genovate Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Genovate Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Genovate Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.77% | NT$312.92 Million ≈ $9.86 Million |
NT$1.51 Billion ≈ $47.46 Million |
+1.92pp |
| 2024-12-31 | 18.86% | NT$299.87 Million ≈ $9.45 Million |
NT$1.59 Billion ≈ $50.10 Million |
-3.59pp |
| 2023-12-31 | 22.45% | NT$359.27 Million ≈ $11.32 Million |
NT$1.60 Billion ≈ $50.42 Million |
+3.09pp |
| 2022-12-31 | 19.36% | NT$302.88 Million ≈ $9.54 Million |
NT$1.56 Billion ≈ $49.29 Million |
+6.76pp |
| 2021-12-31 | 12.60% | NT$190.98 Million ≈ $6.02 Million |
NT$1.52 Billion ≈ $47.75 Million |
0.00pp |
| 2020-12-31 | 12.60% | NT$197.98 Million ≈ $6.24 Million |
NT$1.57 Billion ≈ $49.49 Million |
-3.74pp |
| 2019-12-31 | 16.35% | NT$257.10 Million ≈ $8.10 Million |
NT$1.57 Billion ≈ $49.56 Million |
+1.82pp |
| 2018-12-31 | 14.52% | NT$252.10 Million ≈ $7.94 Million |
NT$1.74 Billion ≈ $54.69 Million |
-0.02pp |
| 2017-12-31 | 14.54% | NT$296.92 Million ≈ $9.35 Million |
NT$2.04 Billion ≈ $64.33 Million |
-3.82pp |
| 2016-12-31 | 18.37% | NT$486.00 Million ≈ $15.31 Million |
NT$2.65 Billion ≈ $83.37 Million |
-3.02pp |
| 2015-12-31 | 21.39% | NT$538.40 Million ≈ $16.96 Million |
NT$2.52 Billion ≈ $79.31 Million |
-- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more